Demonstration of docosahexaenoic acid as a bioavailability enhancer for CYP3A substrates: In vitro and in vivo evidence using cyclosporin in rats

Drug Metabolism and Disposition

Volumn 34, Issue 2, 2006, Pages 305-310

  Hirunpanich, Vilasinee ^a,b   Katagi, Jun ^a,c   Sethabouppha, Benjabhorn ^a,d   Sato, Hitoshi ^a  

^a SHOWA UNIVERSITY   (Japan)

^b MAHASARAKHAM UNIVERSITY   (Thailand)

^c ONO PHARMACEUTICAL CO   (Japan)

^d UBON RATCHATHANI UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450 3A; DOCOSAHEXAENOIC ACID; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; TESTOSTERONE; VALSPODAR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL STRAIN CACO 2; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BIOAVAILABILITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INTESTINE; LIVER METABOLISM; LIVER MICROSOME; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; TRANSPORT KINETICS;

ANIMALS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; DOCOSAHEXAENOIC ACIDS; HUMANS; HYDROXYTESTOSTERONES; INTESTINES; MALE; MICROSOMES, LIVER; P-GLYCOPROTEIN; RATS; RATS, WISTAR;

ANIMALIA;

EID: 31344472724     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.007088     Document Type: Article

References (28)

1. Augustijns PF, Bradshaw TP, Gan LS, Hendren RW, and Thakker DR (1993) Evidence for a polarized efflux system in Caco-2 cells capable of modulating cyclosporin A transport. Biochem Biophys Res Commun 197:360-365.
2. Benet LZ, Izumi T, Zhang Y, Silverman JA, and Wacher VJ (1999) Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Controlled Release 62:25-31.
3. Busnach G, Stragliotto E, Minetti E, Perego A, Brando B, Broggi ML, Nefrologia GC, Renale DTT, and Granda ONC (1998) Effect of n-3 polyunsaturated fatty acids on cyclosporine pharmacokinetics in kidney graft recipients: a randomized placebo-controlled study. J Nephrol 11:87-93.
4. Calabresi L, Villa B, Canavesi M, Sirtori CR, James RW, Bernini F, and Franceschini G (2004) An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia. Metabolism 53:153-158.
5. Connor WE, DeFrancesco CA, and Connor SL (1993) N-3 fatty acids from fish oil. Effects on plasma lipoproteins and hypertriglyceridemic patients. Ann NY Acad Sci 683:16-34.
6. Covington MB (2004) Omega-3 fatty acids. Am Fam Physician 70:133-140.
7. Dahan A and Altman H (2004) Food-drug interaction: grapefruit juice augments drug bioavailability - mechanism, extent and relevance. Eur J Clin Nutr 58:1-9.
8. Das UN (2004) Long chain polyunsaturated fatty acids interact with nitric oxide, superoxide anion and transforming growth factor-beta to prevent human essential hypertension. Eur J Clin Nutr 58:195-203.
9. Engler MM, Engler MB, Goodfriend TL, Ball DL, Yu Z, Su P, and Kroetz DL (1999) Docosahexaenoic acid is an antihypertensive nutrient that affects aldosterone production in SHR. Proc Soc Exp Biol Med 221:32-38.
10. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, and Benet LZ (1995) The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 58:15-19.
11. Harper CR and Jacobson TA (2003) Beyond the Mediterranean diet: the role of omega-3 fatty acid in the prevention of coronary heart disease. Prev Cardiol 6:136-146.
12. Horrocks LA and Yeo YK (1999) Health benefits of docosahexaenoic acid (DHA). Pharmacol Res 40:211-225.
13. Ikeda T, Nishimura K, Taniguchi T, Yoshimura T, Hata T, Kashiyama E, Kudo S, Miyamoto G, Kobayashi H, Kobayashi S, et al. (2001) HAB protocol: in vitro evaluation of drug interaction caused by enzyme inhibition. Xenobio Metab Dispos 16:115-126.
14. Iso H, Sato S, Umemura U, Kudo M, Koike K, Kitamura A, Imano H, Okamura T, Naito Y, and Shimamoto T (2002) Linoleic acid, other fatty acids and the risk of stroke. Stroke 33:2086-2093.
15. Kolars JC, Awni WM, Merion RM, and Watkins PB (1991) First-pass metabolism of cyclosporin by the gut. Lancet 338:1488-1490.
16. Lin JH (2003) Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv Drug Deliv Rev 55:53-81.
17. Liu QY and Tan BK (2000) Effects of cis-unsaturated fatty acids on doxorubicin sensitivity in P388/DOX resistant and P388 parental cell lines. Life Sci 67:1207-1218.
18. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, et al. (1997) Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 62:248-260.
19. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
20. Mouatt JG (2002) Cyclosporin and ketoconazole interaction for treatment of perianal fistulas in the dog. Aust Vet J 80:207-211.
21. Mueller EA, Kovarik JM, VanBree JB, Grevel J, Lucker PW, and Kutz K (1994) Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation. Pharm Res (NY) 11:151-155.
22. Naliwaiko K, Araujo RL, Da Fonseca RV, Castilho JC, Andreatini R, Bellissimo MI, Oliveira BH, Martins EF, Curi R, Fernandes LC, et al. (2004) Effects of fish oil on the central nervous system: a new potential antidepressant? Nutr Neurosci 7:91-99.
23. Parekh K, Trulock E, and Patterson GA (2004) Use of cyclosporine in lung transplantation. Transplant Proc 36:318S-322S.
24. Sanwald P, Blankson EA, Dulery BD, Schoun J, Huebert ND, and Dow J (1995) Isocratic high-performance liquid chromatographic method for the separation of testosterone metabolites. J Chromatogr B Biomed Appl 672:207-215.
25. Spahn-Langguth H and Langguth P (2001) Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur J Pharm Sci 12:361-367.
26. Thakkar RR, Wang OL, Zerouga M, Stillwell W, Haq A, Kissling R, Pierce WM, Smith NB, Miller FN, and Ehringer WD (2000) Docosahexaenoic acid reverses cyclosporin A-induced changes in membrane structure and function. Biochim Biophys Acta 1474:183-195.
27. Trull AK, Tan KK, Tan L, Alexander GJ, and Jamieson NV (1995) Absorption of cyclosporin from conventional and new microemulsion oral formulations in liver transplant recipients with external biliary diversion. Br J Clin Pharmacol 39:627-631.
28. Tsai PJ and Lu SC (1997) Fish oil lowers plasma lipid concentrations and increases the susceptibility of low density lipoprotein to oxidative modification in healthy men. J Formos Med Assoc 96:718-726.